Keeler Thomas Management’s Bristol-Myers Squibb BMY Stock Holding History

Keeler Thomas Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-42,550	Closed	-$2.18M	–	67
2023 Q4	$2.18M	Sell	42,550 -26,876	-39%	-$1.41M	0.86%	44
2023 Q3	$4.05M	Buy	69,426 +4,740	+7%	+$290K	1.5%	24
2023 Q2	$4.14M	Buy	64,686 +15,894	+33%	+$1.07M	1.67%	24
2023 Q1	$3.38M	Buy	+48,792	New	+$3.44M	1.59%	21

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Keeler Thomas Management's BMY Position: Q1 2024 in Review

Keeler Thomas Management sold out of Bristol-Myers Squibb (BMY) in Q1 2024, closing a stake of 42,550 shares — an estimated $2.18M sold.

Keeler Thomas Management first reported a position in BMY in Q1 2023 and held it in 4 quarters. The position peaked at $4.14M in Q2 2023. 2,331 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

Keeler Thomas Management reported no remaining Bristol-Myers Squibb position as of Q1 2024 after selling out during the quarter.
Keeler Thomas Management sold 42,550 Bristol-Myers Squibb shares in Q1 2024, an estimated $2.18M.
Keeler Thomas Management first reported a position in Bristol-Myers Squibb in Q1 2023 and held it in 4 quarters.
Keeler Thomas Management's Bristol-Myers Squibb position peaked at $4.14M in Q2 2023.
2,331 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on Keeler Thomas Management's 13F filing for Q1 2024, filed 7 May 2024.